Aura Biosciences completes enrollment in phase 3 choroidal melanoma trial

June 1, 2026 8:00 AM

Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found